Drug intelligence / Profile preview

MK-8351

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Inhalation

Overview

MK-8351 is a small molecule drug developed by Merck & Co. for the treatment of asthma. It was designed as an inhalant agent and advanced to early clinical trials, specifically targeting respiratory and immune system diseases. The precise mechanism of action remains undisclosed in public sources, but it was investigated for its potential to reduce the early asthmatic response following allergen exposure in the lungs. Clinical development reached Phase 1 before being discontinued, with no evidence of further advancement or approval[1][2][3][7].

Other names: regorafenib + TAS-102-Merck Sharp & Dohme LLC-asthma

Targets

FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on MK-8351.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-8351.

Explore the full profile